Aligos Therapeutics (NASDAQ:ALGS) Releases Quarterly Earnings Results, Beats Expectations By $0.08 EPS

Aligos Therapeutics (NASDAQ:ALGS) released its earnings results on Thursday. The company reported ($2.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.29) by $0.08, FiscalAI reports. Aligos Therapeutics had a negative net margin of 1,106.72% and a negative return on equity of 28.16%. The business had revenue of $2.83 million for the quarter, compared to analysts’ expectations of $0.25 million.

Aligos Therapeutics Stock Down 5.3%

Shares of ALGS traded down $0.34 during mid-day trading on Thursday, reaching $6.03. 87,644 shares of the stock traded hands, compared to its average volume of 454,505. The firm has a market cap of $37.33 million, a price-to-earnings ratio of -0.70 and a beta of 2.28. The stock has a fifty day simple moving average of $7.10 and a 200 day simple moving average of $8.16. Aligos Therapeutics has a 12-month low of $4.20 and a 12-month high of $13.69.

Institutional Trading of Aligos Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in ALGS. Woodline Partners LP bought a new stake in shares of Aligos Therapeutics in the first quarter worth $2,602,000. Geode Capital Management LLC increased its stake in shares of Aligos Therapeutics by 21.3% in the second quarter. Geode Capital Management LLC now owns 34,048 shares of the company’s stock worth $246,000 after buying an additional 5,978 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of Aligos Therapeutics in the second quarter worth $100,000. Vanguard Group Inc. increased its stake in shares of Aligos Therapeutics by 22.8% in the third quarter. Vanguard Group Inc. now owns 171,689 shares of the company’s stock worth $1,683,000 after buying an additional 31,913 shares during the last quarter. Finally, Squarepoint Ops LLC increased its stake in shares of Aligos Therapeutics by 64.0% in the third quarter. Squarepoint Ops LLC now owns 30,493 shares of the company’s stock worth $299,000 after buying an additional 11,904 shares during the last quarter. Institutional investors own 60.43% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Wall Street Zen cut shares of Aligos Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Aligos Therapeutics in a research report on Wednesday, March 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aligos Therapeutics in a research report on Monday, April 20th. UBS Group assumed coverage on shares of Aligos Therapeutics in a research report on Wednesday, January 7th. They set a “buy” rating and a $20.00 price target on the stock. Finally, Westpark Capital assumed coverage on shares of Aligos Therapeutics in a research report on Thursday, March 26th. They set a “buy” rating and a $48.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $41.50.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.